Epigenomics AG / Key word(s): Miscellaneous
12.12.2013 / 08:45
Berlin, Germany, and U.S.A., December 12, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d’Assurance du Corps de Santé Français), the leading French supplementary insurance provider for the medical community, will provide the blood-based Septin9 test for the early detection of colorectal cancer (CRC) as part of their additional health insurance program. MACSF will reimburse EUR 50 on what its policy holders pay for undergoing Septin9 testing.
MACSF offers about 800.000 policy holders from the medical community and their families, such as doctors from the private and public sector, other medical or paramedical workers including medical students an additional health insurance, called ‘Mutuelle’. After Swiss Life announced to provide Septin9 as part of its preventive health program in July 2012, MACSF is the second healthcare provider in France and the first ‘Mutuelle’ to reimburse blood-based colorectal cancer screening.
Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented: ‘We are extremely pleased to experience this growing support by French insurance providers. The fact that also MACSF now offers blood-based Septin9 tests to its customers shows the importance of an alternative convenient and non-invasive screening method. And, as their policy holders originate primarily from the medical community, we also hope to raise awareness and convince doctors of our Septin9-based test Epi proColon(R), so that they increasingly recommend it to their patients’.
– Ends –
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A and China. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.
MACSF Group (Mutuelle d’Assurance du Corps de Santé Français) is for over 75 years the leading insurance provider for healthcare professionals in France. Its mission is to provide supplementary insurance services for private or work-related risks for its members working in the private or public healthcare space.
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
For US press inquiries:
Epigenomics legal disclaimer
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.
End of Corporate News
12.12.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Kleine Präsidentenstraße 1|
|Phone:||+49 30 24345-0|
|Fax:||+49 30 24345-555|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|